Pannex Therapeutics is an early-stage biopharmaceutical company based in New York City, developing a platform of first-in-class Pannexin 1 channels (Panx1) blockers to fight cancer. Panx1 is a novel pharmacological target that plays a key role in multiple pathways of cancer progression, such as proliferation, invasion, angiogenesis, immune evasion and metastasis. By blocking Panx1, Pannex Therapeutics aims to stop the growth, spread, and survival of cancer cells in various types of tumors.